Cancer incidence is increasing worldwide and in the UK it is estimated that 1 in 2 people born after 1960 will be diagnosed with some form of cancer in their lifetime. New tests that analyse circulating tumour DNA (ctDNA) in the bloodstream of patients with cancer have the potential to transform the management of the disease.
ctDNA technologies are a great example of personalised healthcare in action. Currently ctDNA technologies are being implemented in a small subset of lung cancer patients, potentially opening up the option of new therapies better suited to their tumours. We want to make sure that the healthcare system learns from areas where ctDNA technologies are already being used to ensure it is implemented effectively and efficiently in the future, in order to bring the greatest benefits to patients.
We are investigating ctDNA technologies, the cancers in which they could have an impact and the most pressing issues that are affecting implementation of ctDNA testing within the health system.
Laura provides support for a variety of projects at PHG Foundation, including infectious disease genomics.More about Laura